|Videos|October 31, 2016

University of Minnesota Antimicrobial Stewardship Program Tackles HAIs

Susan Kline, MD, MPH, associate professor of medicine, Division of Infectious Diseases and International Medicine, medical director for Infection Control, lead physician for Antibiotic Stewardship, at the University of Minnesota, discusses the growing problem of antibiotic-resistance in hospital-acquired infections.

Susan Kline, MD, MPH, associate professor of medicine, Division of Infectious Diseases and International Medicine, medical director for Infection Control, lead physician for Antibiotic Stewardship, at the University of Minnesota, discusses the growing problem of antibiotic-resistance in hospital-acquired infections.

Interview Transcript (slightly modified for readability)

“We have, over several years, been able to see a decrease in antibiotic-resistant hospital-acquired infections. And so, when we started our program, that was one of the things that we hoped we would achieve. We were worried about the emergence of MRSA, vancomycin-resistant enterococci [VRE] and then also, the gram-negative resistance, that really has emerged since we began the program.

One of our goals was to prevent further emergence of these antibiotic-resistant hospital-acquired infections. Over time, we have been able to see some declines, in particular with the gram-positive HAIs, like MRSA and VRE infections. We’ve actually began to see more gram-negative resistance, though, during that time period [since the launch of our program]. I think that probably reflects the trend that’s going on around the country, and around the world, as well. That’s an ongoing problem that we’re still trying to combat.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.